ALGS
Aligos Therapeutics, Inc.
There isn't enough reported data to score ALGS yet.
ALGS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ALGS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ALGS PE Valuation
ALGS has no meaningful PE right now: it lost money over the past year.
ALGS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ALGS's losses to shrink, with revenue declining.
ALGS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$46.75 | +$19.75 |
| Q2 2023 | -$47.50 | +$27.50 |
| Q1 2023 | -$48.50 | +$34.50 |
| Q4 2022 | -$56.25 | +$24.25 |
ALGS is still losing money, but far less than before: $19.80 per share over the past year, against $83.00 at its worst in early 2022.
ALGS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +282% |
| Q1 2026 | $2.8M | +810% |
| Q4 2025 | $169K | -72% |
| Q3 2025 | $741K | -41% |
| Q2 2025 | $965K | -9% |
| Q1 2025 | $311K | -55% |
| Q4 2024 | $606K | -9.8% |
| Q3 2024 | $1.3M | +15% |
ALGS's revenue is recovering but still below its 2023 peak: $3M last quarter, up 282% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -774% | +3054 points |
| Q1 2026 | -952% | +5236 points |
| Q4 2025 | -12908% | -9515 points |
| Q3 2025 | -3827% | -2217 points |
| Q2 2025 | -1924% | +566 points |
| Q1 2025 | -6187% | -3011 points |
| Q4 2024 | -3393% | +475 points |
| Q3 2024 | -1610% | +147 points |
ALGS's operating margin was −774% last quarter, up 1151 points from the same quarter a year ago.
ALGS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5M | +$25.8M |
| Q2 2026 | -$25M | -$9.4M |
| Q1 2026 | -$23.1M | -$2.2M |
| Q3 2025 | -$24.3M | -$4.2M |
| Q2 2025 | -$15.5M | +$4M |
| Q1 2025 | -$20.9M | +$1.8M |
| Q3 2024 | -$20.1M | +$235K |
| Q2 2024 | -$19.5M | -$5.9M |
ALGS has burned cash in almost every quarter: −$68M over the past year, against −$81M the year before.
ALGS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +31.1K shares |
| 1 year | +1.1% | +111K shares |
| 3 years | +513% | +8.8M shares |
ALGS has 10M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
ALGS Net Leverage
ALGS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALGS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 8.1 | Oversold |
ALGS's weekly RSI is 28 (oversold) and its Stochastic is 8 (oversold).
ALGS PE vs Healthcare Sector
ALGS has no meaningful PE right now: it lost money over the past year.
ALGS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 57% below |
| 20 week MA | $5.29 | 63% below |
| 50 week MA | $6.56 | 70% below |
| 100 week MA | $9.83 | 80% below |
| 200 week MA | $15.4 | 87% below |
ALGS is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
ALGS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $371.3 | $721.3 | +94% |
| 2021 | $721.3 | $296.5 | -59% |
| 2022 | $296.5 | $22.7 | -92% |
| 2023 | $22.7 | $16.6 | -27% |
| 2024 | $16.6 | $41.2 | +148% |
| 2025 | $41.2 | $10.1 | -75% |
| 2026 YTD | $10.1 | $1.98 | -80% |
ALGS's yearly returns have swung widely, from +148% in 2024 to −92% in 2022. It's down 80% so far in 2026.